Mesenchymal stem cells transmigrate over the endothelial barrier

Schmidt, Annette; Ladage, Dennis; Steingen, Caroline; Brixius, Klara; Schinköthe, Timo; Klinz, Franz‐Josef; Schwinger, Robert H. G.; Mehlhorn, Uwe; Bloch, Wilhelm

doi:10.1016/j.ejcb.2006.05.015

Cited by 107 publications

(80 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After this time, the hearts were analysed and it was revealed that the endothelial tight junctions had been abolished and MSC had become associated with the endothelial cells. Electron microscopy revealed that, even after 30 min of perfusion, approximately 30% of the perfused MSC had transmigrated across the endothelium -this percentage rose to 50% after 60 min but remained constant thereafter (Schmidt et al, 2006). Elsewhere, transmigration across the endothelium into cardiac tissue of MSC injected into the ventricular cavity has been observed in rats pre-treated with TNF-a or in rats 24 h after ischaemia (30 min)-reperfusion injury (Segers et al, 2006).…”

Section: +mentioning

confidence: 91%

“…When these cells were injected intravenously into the tail veins of rats they were later observed in the brain after artificial cerebral ischaemia (Chen et al, 2001). Similarly, MSC have been shown to migrate to the injured myocardium (Devine et al, 2001;Jiang et al, 2005) so it was not surprising that, more recently, the first microscopic evidence of the ability of MSC to transmigrate across the endothelial barrier was reported (Schmidt et al, 2006). They assembled a co-culture of endothelial cells (derived from differentiated embryonic stem cells) and MSC from human BM aspirates.…”

Section: Integrins and Their Role In Msc Firm-adhesion And Transendotmentioning

confidence: 99%

“…. The process of MSC transendothelial migration appears to be similar to that of leucocytes and HSC, albeit under the control of specific adhesion molecules elucidated largely by Ruster et al (2006); Segers et al (2006) and Schmidt et al (2006). 1 Has been shown to be inhibited by: a neutralising P-selectin antibody, fucosidase or O-sialoglucoprotein-endopeptidase treatment of MSC, the absence of Ca 2+ /Mg…”

Section: Integrins and Their Role In Msc Firm-adhesion And Transendotmentioning

confidence: 99%

See 2 more Smart Citations

Recent advances into the understanding of mesenchymal stem cell trafficking

et al. 2007

View full text Add to dashboard Cite

SummaryThe use of adult stem cells to regenerate damaged tissue circumvents the moral and technical issues associated with the use of those from an embryonic source. Mesenchymal stem cells (MSC) can be isolated from a variety of tissues, most commonly from the bone marrow, and, although they represent a very small percentage of these cells, are easily expandable. Recently, the use of MSC has provided clinical benefit to patients with osteogenesis imperfecta, graft-versushost disease and myocardial infarction. The cellular cues that enabled the MSC to be directed to the sites of tissue damage and the mechanisms by which MSC then exert their therapeutic effect are becoming clearer. This review discusses the relative therapeutic importance of the ability of MSC to differentiate into multiple cell lineages or stimulate resident or attracted cells via a paracrine mode of action. It also reviews recent findings that MSC home to damaged tissues in a similar, but somewhat distinct, manner to that of leucocytes via the utilisation of adhesion molecules, such as selectins and integrins, and chemokines and their receptors in a manner reminiscent of leucocytes trafficking from the blood stream to inflammatory sites.

show abstract

Section: +mentioning

confidence: 91%

Section: Integrins and Their Role In Msc Firm-adhesion And Transendotmentioning

confidence: 99%

Section: Integrins and Their Role In Msc Firm-adhesion And Transendotmentioning

confidence: 99%

See 1 more Smart Citation

Recent advances into the understanding of mesenchymal stem cell trafficking

et al. 2007

View full text Add to dashboard Cite

show abstract

“…MSCs have natural stealth properties and are able to cross biologic barriers. 52,53 Thus, MSCs hold a tremendous potential for being employed in anticancer therapy as drug delivery vehicles. In addition, nanoparticle-labeled MSC homing to cancerous tissue would add great benefit to visualization of tumors and/or metastases and their response to treatment.…”

Section: Discussionmentioning

confidence: 99%

Skin-derived mesenchymal stem cells as quantum dot vehicles to tumors

Dapkutė¹,

Steponkienė²,

Bulotienė³

et al. 2017

IJN

View full text Add to dashboard Cite

Purpose Cell-mediated delivery of nanoparticles is emerging as a new method of cancer diagnostics and treatment. Due to their inherent regenerative properties, adult mesenchymal stem cells (MSCs) are naturally attracted to wounds and sites of inflammation, as well as tumors. Such characteristics enable MSCs to be used in cellular hitchhiking of nanoparticles. In this study, MSCs extracted from the skin connective tissue were investigated as transporters of semiconductor nanocrystals quantum dots (QDs). Materials and methods Cytotoxicity of carboxylated CdSe/ZnS QDs was assessed by lactate dehydrogenase cell viability assay. Quantitative uptake of QDs was determined by flow cytometry; their intracellular localization was evaluated by confocal microscopy. In vitro tumor-tropic migration of skin-derived MSCs was verified by Transwell migration assay. For in vivo migration studies of QD-loaded MSCs, human breast tumor-bearing immunodeficient mice were used. Results QDs were found to be nontoxic to MSCs in concentrations no more than 16 nM. The uptake studies showed a rapid QD endocytosis followed by saturating effects after 6 h of incubation and intracellular localization in the perinuclear region. In vitro migration of MSCs toward MDA-MB-231 breast cancer cells and their conditioned medium was up to nine times greater than the migration toward noncancerous breast epithelial cells MCF-10A. In vivo, systemically administered QD-labeled MSCs were mainly located in the tumor and metastatic tissues, evading most healthy organs with the exception being blood clearance organs (spleen, kidneys, liver). Conclusion Skin-derived MSCs demonstrate applicability in cell-mediated delivery of nanoparticles. The findings presented in this study promise further development of a cell therapy and nanotechnology-based tool for early cancer diagnostics and therapy.

show abstract

“…32 Several evidences support that MSC can home to injured or inflamed tissues migrating across endothelial cell layers. [33][34][35] However, the mechanism by which MSC home to the tissue and migrate across endothelium is not yet fully understood.…”

Section: Potential Clinical Application Of Mscmentioning

confidence: 99%